Pogoda Tree (Styphnolobium japonicum / Sophora japonica): A Comprehensive Reference
1. Identity and Botanical Classification
The ingredient marketed in dietary supplements under the common name pogoda tree — also rendered "pagoda tree" — derives from the species Styphnolobium japonicum (L.) Schott, a plant whose earlier and still widely cited scientific name is Sophora japonica L. The pogoda tree, scientifically known as Styphnolobium japonicum (previously Sophora japonica), has a long-standing history in traditional medicine, particularly in East Asia.
Sophora japonica (Fabaceae), also known as Huai (Chinese: 槐), is a medium-sized deciduous tree commonly found in China, Japan, Korea, Vietnam, and other countries. It belongs to the subfamily Faboideae of the family Fabaceae (the legume family). The genus Sophora is deemed one of the most remarkable genera of Fabaceae, the third largest family of flowering plants; the genus comprises approximately 52 species, 19 varieties, and 7 forms, widely distributed in Asia and mildly in Africa.
Common names for the tree include:
- Pogoda tree (marketing / supplement name)
- Japanese pagoda tree (English common name)
- Chinese scholar tree
- Huai or Huai shu (Chinese)
- Huaihua — referring specifically to the dried flowers
- Huaimi — referring specifically to the flower buds
Every part of this plant, including the flowers, buds, leaves, bark, and seeds, is used as medicine in Asia, particularly in China, Japan, and Korea. The plant parts used medicinally carry distinct pharmacopeial names:
- Flos Sophorae (Huaihua): the dry flowers
- Flos Sophorae Immaturus (Huaimi or Huai Mi): the dry flower buds
- Fructus Sophorae (Huai Jiao): the dry mature fruits
The dry flowers (Huaihua or Flos Sophorae) and the flower buds (Huaimi or Flos Sophorae Immaturus) are included in both the Chinese Pharmacopoeia and the European Pharmacopoeia. The dried fruits and seeds of Styphnolobium japonicum (L.) Schott (syn. Sophora japonica L.) are used in traditional Chinese medicine and known as Fructus Sophorae or Huai Jiao.
2. Common Forms and Preparations
The dried flower and flower bud of Styphnolobium japonicum (L.) Schott have long been used as herbal medicines in Asia; today they are marketed as dietary supplements in the United States for their anti-oxidative properties and as a source of flavonoids, including rutin and quercetin.
Commercially available preparations include:
- Standardized dry extracts of the flower or flower bud, typically standardized to a declared rutin content. The United States Pharmacopeia defines Japanese sophora materials by plant part and preparation, including dry extract preparation from flowers or flower buds; a practical reference is the USP–NF Japanese Sophora Flower Dry Extract monograph, which describes raw material identity and extraction preparation details.
- Standardized seed extracts (20:1 and other ratios) — quercetin is a naturally occurring flavonoid found in various plants, including the seeds of Sophora japonica, and standardized extracts such as 20:1 Sophora japonica seed extract provide concentrated quercetin.
- Capsules and tablets containing rutin or quercetin derived from the plant. Capsules or tablets typically contain 50–500 mg rutin per serving.
- Herbal teas / infusions made from the dried flower buds.
- Topical preparations, such as creams or gels containing rutin or rutoside fractions, used for localized vascular applications. Rutin- or rutoside-containing topicals exist for localized capillary comfort (e.g., perianal, leg, or facial products).
- Traditional decoctions (boiled preparations) are the classical oral form used in East Asian medicine.
Three entries are listed in the Chinese Pharmacopoeia; Huaimi (Flos Sophora immaturus) is the dry flower buds of S. japonica collected in summer, and the rutin content in the flower buds must not be less than 20%; it is used mainly as a hemostatic agent for the treatment of different hemorrhagic diseases. The rutin content in flowers must not be less than 8%.
3. Traditional and Historical Use
3.1 Traditional Chinese Medicine (TCM)
The extract has a rich history in traditional Eastern medicine, particularly in Chinese medicine, where it has been documented for over 2,000 years; known as "Huai Hua" or "Huai Mi," it was first mentioned in the ancient Chinese pharmacopeia Shennong Ben Cao Jing.
The use of this plant has been recorded in classical medicinal treatises of ancient China, and it is currently recorded in both the Chinese Pharmacopoeia and the European Pharmacopoeia. S. japonica is used in traditional medicine to cool the blood and stop bleeding.
The flower buds and fruits of S. japonica, known as Flos Sophorae Immaturus and Fructus Sophorae in China, are most commonly used in Asia (especially in China) to treat hemorrhoids, hematochezia, hematuria, hematemesis, hemorrhinia, uterine or intestinal hemorrhage, arteriosclerosis, headache, hypertension, dysentery, dizziness, and pyoderma.
In the framework of TCM, the plant was classified by its thermal and functional characteristics. Traditional practitioners utilized it primarily for its hemostatic properties to control bleeding, especially for hemorrhoids, uterine bleeding, and hematemesis; its cooling nature made it valuable for treating conditions characterized by "heat" in traditional Chinese medicine; beyond hemostasis, it was used for reducing fever, clearing heat toxins, and alleviating inflammatory conditions.
According to classical Chinese pharmacopeial texts, the plant's two primary therapeutic actions in TCM were: cooling the blood and stopping bleeding — used for conditions where "blood heat" causes excessive bleeding, like nosebleeds, hemorrhoids — and clearing liver fire: when the liver is described as "overheated," Huaihua is used to calm it down, addressing symptoms such as red eyes, headaches, or dizziness.
TCM practitioners might prescribe it as a decoction (boiled into a tea), pill, or powder, typically at doses of 5–10 grams daily.
3.2 Use in Japan, Korea, and Vietnam
Dried flowers and buds of Sophora japonica (Huaihua) are a medicinal herb used in China, Japan, and Korea to treat hemorrhoids and hematemesis. Its use across these neighboring cultures reflects a shared tradition in East Asian herbal medicine stretching from antiquity into the present day.
3.3 European Recognition
The Japanese pagoda tree has a long history of ethnopharmacological use; its use is recorded in the classical medicinal literature of ancient China and has also been recorded in both the European Pharmacopoeia and the Chinese Pharmacopoeia. This dual pharmacopeial recognition—across both Eastern and Western regulatory contexts—distinguishes it from many herbs documented only in a single tradition.
4. Phytochemistry: Key Constituents and Active Compounds
The principal components of S. japonica include flavonoids, isoflavonoids, triterpene and its glycosides, alkaloids, phospholipids (PLs), amino acids, microelements, and polysaccharides. Sophora species are recognized to be substantial sources of broad-spectrum biopertinent secondary metabolites, namely flavonoids, isoflavonoids, chalcones, chromones, pterocarpans, coumarins, benzofuran derivatives, sterols, saponins (mainly triterpene glycosides), oligostilbenes, and mainly alkaloids.
4.1 Major Flavonoids
Among the compounds of S. japonica, kaempferol, quercetin, rutin, isorhamnetin, genistein, and sophoricoside are the major active constituents. These have been confirmed analytically by multiple studies. HPLC-UV analysis identified five flavonoid compounds in S. japonica flower extract: rutin, quercetin, genistein, kaempferol, and isorhamnetin.
- Rutin (quercetin-3-O-rutinoside): The predominant constituent of the flower buds and flowers. The flower buds (Huai Mi) and flowers (Huai Hua) of S. japonicum (collectively Flos Sophorae) contained rutin as the main flavonoid. Japanese pagoda tree extract — prepared from the flower or flower bud of Styphnolobium japonicum (syn. Sophora japonica) — is a flavonoid-rich ingredient best known for delivering rutin and related quercetin glycosides.
- Quercetin: A flavonol aglycone formed from rutin by enzymatic hydrolysis. It is recognized for its potent antioxidant and anti-inflammatory properties.
- Sophoricoside: An isoflavone glycoside unique to this species and related Sophora plants. Sophoricoside is a glycoside of the isoflavone genistein, a well-known antioxidant.
- Genistein: A phytoestrogenic isoflavone present particularly in the fruits and seeds. The isoflavone aglycone genistein and flavonol aglycone kaempferol were found to be the main phytoestrogens in the naringinase-treated phytoextract of S. japonica seeds.
- Kaempferol: A flavonol with demonstrated antioxidant and anti-inflammatory activity.
- Isorhamnetin: A flavonol methyl ether and metabolite of quercetin.
4.2 Other Phytochemicals
Beyond flavonoids, the fruit and other plant parts contain a broader chemical matrix. Main components of Sophora japonica include flavones, tetraglycosides, isoflavones, isoflavone tetraglycosides, triterpene glycosides, phospholipids, alkaloids, amino acids, and polysaccharides. The flowers of S. japonicum are further enriched by essential minerals such as iron, important in the treatment of anemia, and magnesium, serving as a catalyst in numerous enzymatic reactions. The plant contains a variety of bioactive compounds such as flavonoids, glycosides, alkaloids, and polysaccharides, but its pharmacological effects are primarily attributed to the antioxidant activity of flavonoids like kaempferol, quercetin, and genistein and their respective glycosides like rutin, isorhamnetin, and sophoricoside.
5. Mechanisms of Action
5.1 Antioxidant Activity
The flavonoid components of Sophora japonica scavenged superoxide anion and 1,1-diphenyl-2-picrylhydrazyl (DPPH) free radicals. Rutin's antioxidant capacity is partly attributed to its structural features: rutin contains two bound sugar molecules, which enhance its antioxidant effects on the brain.
5.2 Vascular and Hemostatic Mechanisms
Historically used in East Asian medicine for cooling heat, supporting vascular integrity, and easing bleeding, the extract now appears in modern supplements aimed at capillary strength, venous tone, and skin or mucosal comfort; thanks to high rutin content, it sits at the intersection of food and pharmacology, with strong antioxidant capacity and evidence for microvascular symptom relief in chronic venous disease, largely via rutoside derivatives.
5.3 Anti-inflammatory Mechanisms
Isorhamnetin, kaempferol, genistein, quercetin, and rutin are the principal active compounds of S. japonica; these phytochemicals have been investigated to exert anti-inflammatory, antioxidant, anti-atherosclerotic, and anti-osteoporotic activities. At the cellular level, quercetin functions by scavenging free radicals, modulating inflammatory pathways, and influencing cellular signaling.
5.4 Phytoestrogenic Mechanisms
Seeds of S. japonica extract prevented bone loss, partly by inhibiting osteoclastic activity; the alcoholic extract showed significant estrogenic activity after naringinase treatment; kaempferol was nearly equipotent to genistein as an estrogen agonist, which was reported to prevent osteoporosis.
5.5 Neuroprotective Mechanisms (Preclinical)
Despite widespread uses in Chinese and European medicine, Styphnolobium japonicum had not been extensively investigated for its potential to protect against neurodegenerative processes and to promote resistance to oxidative stress until recently; a hydroalcoholic extract from Chinese scholar tree fruits was evaluated for neuroprotective activities using Caenorhabditis elegans as an in vivo model. The fruit extract decreased α-synuclein accumulation in NL5901 worms relative to the solvent control group. These findings are preclinical only and have not been replicated in human studies.
6. Scientific Evidence by Area of Use
The following section distinguishes between traditional use claims and the available scientific evidence. It is important to note that most mechanistic studies concern isolated constituents (primarily rutin, quercetin, and their semi-synthetic derivatives), not whole-plant S. japonica extracts in clinical settings. Some small-scale clinical studies have explored the effects of pogoda tree-derived rutin on circulatory health, reporting potential benefits in capillary strength and venous function; however, comprehensive clinical trials in humans remain limited, and evidence regarding its efficacy for specific health conditions is not yet conclusive.
6.1 Venous and Circulatory Health
Traditional claim: Both the flower and flower buds have the same medicinal uses with significant biological activity in the treatment of arteriosclerosis and hypertension.
Scientific evidence: The most clinically studied derivatives of rutin from S. japonica are the semi-synthetic hydroxyethylrutosides (HR, also called oxerutins), sold under brand names such as Venoruton® (Switzerland) and Paroven® (United Kingdom). Hydroxyethylrutosides (HR) are semisynthetic derivatives sold as standardized products for the treatment of chronic venous insufficiency (CVI).
There are numerous studies reporting benefits such as less swelling of the legs and ankles, and a placebo-controlled and randomized trial confirmed that rutin reduces free radicals in patients with chronic venous insufficiency (CVI) and venous microangiopathy.
In an 8-month study of patients with severe chronic venous insufficiency, each person received a daily dosage of 1 g, 2 g, or none at all; additionally, they all wore specialized compression stockings; while all experienced improvement, the best results were seen with the highest dosage of Venoruton, and the stockings alone were the least effective treatment.
In another study of 22 people with varicose veins and venous insufficiency, the higher dose had a faster effect than the lower dose (2 g/day vs. 1 g/day), but everyone experienced benefits in just 8 days.
Venoruton (hydroxyethylrutoside) successfully controlled leg swelling in 4 clinical trials on over 300 people flying for 7–11 hours.
Evidence strength: The evidence for the efficacy of hydroxyethylrutosides in CVI is inconclusive. A 2015 systematic review of HR identified relevant randomized controlled trials but noted significant heterogeneity. The evidence supporting venous symptom relief is moderate in strength for semi-synthetic rutoside preparations; evidence for natural rutin supplements specifically derived from S. japonica (as opposed to isolated or modified derivatives) is weaker and less standardized. Overall, the benefits of rutosides are most solidly supported for short-term symptom relief in CVI.
6.2 Hemorrhoids
Traditional claim: Dried flowers and buds of Sophora japonica are a medicinal herb used in China, Japan, and Korea to treat hemorrhoids.
Scientific evidence: Rutin improved bleeding, pain, and inflammation in 2 clinical trials on 150 women with hemorrhoids due to pregnancy; a mixture of rutin and other flavonoids (diosmin, hesperidin, and quercetin) reduced hemorrhoid symptoms without causing adverse effects in another trial on 154 people; although limited, the evidence suggests that rutin may help with hemorrhoids.
Evidence strength: Preliminary to moderate; existing human trials typically test rutin in combination with other flavonoids or use semi-synthetic derivatives rather than whole S. japonica extract. Rutosides have been used to reduce pain and swelling in hemorrhoidal disease, with variable but sometimes positive results; overall, benefits are most solidly supported for short-term symptom relief in CVI rather than hemorrhoids specifically.
6.3 Wound Healing
Traditional claim: Wounds and sores are listed among the traditional applications of the pogoda tree.
Scientific evidence: While some in vitro and animal studies have shown that extracts from the pagoda tree contain bioactive flavonoids (such as rutin and quercetin) with antioxidant, anti-inflammatory, and potential wound-healing effects, there is a lack of robust clinical evidence or comprehensive studies that directly confirm efficacy and safety for wound and sore treatment in humans. Most available research focuses on the plant's vascular-protective and anti-hemorrhagic effects rather than direct wound healing.
Evidence strength: Preliminary; limited to in vitro and animal models. While traditional use is well-documented, the scientific evidence supporting its effectiveness for wounds and sores remains preliminary.
6.4 Inflammation and Arthritis
Scientific evidence (preclinical): Paw edema and arthritic scores of CFA rats were evaluated to investigate the anti-arthritis effect of S. japonica flower extract (SJF); a rat model of arthritis was established by intradermal administration of 0.1 mL of CFA; the injection of CFA induced a gradual increase in paw edema on day 7, and the effect was sustained until the end of the experiment. These animal studies provide biological plausibility for anti-inflammatory use, but no clinical trials in humans have been published for this indication.
Evidence strength: Animal and in vitro only; no controlled human trials identified for arthritis specifically.
6.5 Osteoporosis and Bone Health
Scientific evidence (preclinical and limited human): Sophora flavonoids and isoflavonoids, especially genistein, sophoricoside, sophorabioside, 8-prenyl kaempferol, formononetin, maackiain, sophoraflavonoloside, nicotiflorin, and rutin, showed anti-osteoporosis effects through several pathways. Fructus Sophorae (FS) or Huaijiao, the dry mature fruit of S. japonica, was demonstrated to prevent bone loss in an ovariectomized rat model.
Research has shown that extracts of Fructus sophorae in dichloromethane have anti-osteoporotic potential; genistein and daidzein were shown to elevate osteocalcin levels, stimulate alkaline phosphatase activity, and promote matrix mineralization in C3H10T1/2 pluripotent mesenchymal cells in a dose-dependent manner; this evidence highlights the potential of these phytoestrogens to enhance osteoblastic function and maintain bone integrity.
Compounds from S. japonica fruits have shown beneficial effects on osteoporosis in rats and menopausal symptoms in women.
Evidence strength: Mostly preclinical (cell culture and animal models); limited and preliminary human data specifically on menopausal symptoms. More rigorous clinical trials are needed.
6.6 Neuroprotection and Cognitive Function
Scientific evidence (preclinical): A hydroalcoholic extract from Chinese scholar tree fruits was evaluated for neuroprotective activities that could be linked to its antioxidant properties using Caenorhabditis elegans as a well-established in vivo model. Treatment with the extract caused a delay in time of paralysis compared to the solvent control group in models of amyloid-β-induced toxicity.
Evidence strength: Entirely preclinical (C. elegans invertebrate model). No human clinical data are available for neuroprotective effects of S. japonica extracts.
6.7 Skin Health and Photoaging
Scientific evidence (preclinical and limited topical): Sophoricoside is a glycoside of genistein; both genistein and sophoricoside have been reported to have beneficial effects on various diseases, and a study has added photo-aging to the list of targeted disorders that these antioxidants can address.
In a clinical trial on 40 middle-aged people, a topical cream with rutin increased skin elasticity and decreased the length, area, and number of wrinkles. This remains a single small study with limited external validity.
Evidence strength: Preliminary; primarily animal and in vitro data, with one small human topical trial.
6.8 Antimicrobial and Antitumor Activity
Numerous studies describe beneficial biological effects of different S. japonica extracts, such as antibacterial, antihyperglycemic, anti-obesity, antihemorrhagic, cardiovascular, antitumor, anti-angiogenic, anti-atherosclerotic, antioxidant, neuroprotective, and most commonly anti-inflammatory and anti-osteoporotic activities. These reported properties are largely derived from in vitro or preclinical animal experiments and have not been confirmed in human clinical trials.
Evidence strength: Preclinical only; no controlled human evidence is currently available for antimicrobial or antitumor indications.
6.9 Cerebrovascular / Cerebral Infarction
A review aimed to provide an overview of the pharmacology of Sophora japonica, in particular its effects and mechanisms in reducing cerebral infarction. The review identified mechanisms via free-radical scavenging, anti-platelet aggregation, and anti-inflammatory pathways associated with rutin and quercetin content. Free radical scavenging activity was demonstrated in Ginkgo biloba leaves which contain quercetin and rutin, which have free radical scavenging activity — an analogy relevant to understanding the mechanism in S. japonica.
Evidence strength: Mechanistic/preclinical review evidence only; no human RCTs were identified for S. japonica specifically in the context of cerebrovascular events.
7. Body Systems Associated with Pogoda Tree Use
Based on converging traditional use and pharmacological research, the following body systems are most associated with pogoda tree preparations:
- Cardiovascular and circulatory system: Capillary integrity, venous tone, vascular permeability, and anti-hemorrhagic effects.
- Musculoskeletal system: Bone mineral density and osteoblast function via phytoestrogenic flavonoids.
- Integumentary system (skin): Antioxidant protection, wound healing, and photoaging.
- Neurological system: Antioxidant-mediated neuroprotection (preclinical only).
- Gastrointestinal and anorectal system: Treatment of hemorrhoids and gastrointestinal bleeding (traditional and partially human-evidence-supported).
- Immune and inflammatory system: Modulation of cytokine production and oxidative stress pathways.
- Endocrine/reproductive system: Phytoestrogenic activity relevant to menopausal health.
These phytochemicals contribute to protective mechanisms against oxidative stress, skin photoaging, osteoporosis, cardiovascular dysfunction, and metabolic disorders such as diabetes and obesity; the Japanese pearl tree has long been valued in traditional Chinese medicine and is now gaining renewed attention for its multifaceted pharmacological potential, with a review synthesizing current knowledge of bioactive compounds — particularly flavonoids such as genistein, rutoside, quercetin, and sophoricoside — and their broad-spectrum biological activities, including antioxidant, anti-inflammatory, antimicrobial, neuroprotective, and wound-healing effects.
8. Dosage Forms and Dosages Reported in Studies
Dosing information available in the scientific literature relates primarily to constituent-specific forms rather than to whole S. japonica extract. No single universal standardized dose has been established for the pogoda tree as a dietary supplement.
- Traditional TCM dose (decoction): TCM practitioners might prescribe it as a decoction (boiled into a tea), pill, or powder, typically at doses of 5–10 grams daily.
- Rutin (natural, from S. japonica extract): Capsules or tablets typically contain 50–500 mg rutin per serving. No specific standardized clinical dose for natural rutin from this plant has been established in peer-reviewed human trials.
- Hydroxyethylrutosides (semi-synthetic rutoside derivatives) in CVI trials: In an 8-month study of patients with severe chronic venous insufficiency, each person received a daily dosage of 1 g or 2 g. The higher dose (2 g/day vs. 1 g/day) had a faster effect, but both groups experienced benefits.
- Quercetin (from S. japonica seed extract): A systematic review analyzed 34 studies on quercetin doses ranging from 500–3,000 mg in relation to exercise performance and recovery.
- Chinese Pharmacopoeia flower bud standard: The rutin content in flower buds must not be less than 20%. The rutin content in flowers must not be less than 8%.
Investigators and formulators should note that in many clinical trials and prescription products, "rutosides" refer to hydroxyethylrutosides (oxerutins), a standardized mixture of hydroxyethylated rutin derivatives; troxerutin is another semi-synthetic rutoside derived from rutin but modified to improve water solubility and oral absorption; because of these differences, two products labeled with "rutoside" can behave quite differently in the body.
9. Safety, Adverse Effects, and Drug Interactions
9.1 General Safety Profile
The dried flower and flower bud of Styphnolobium japonicum have long been used as herbal medicines in Asia; today they are marketed as dietary supplements in the United States for their anti-oxidative properties and as a source of flavonoids; a comprehensive safety review focused on the safety of S. japonicum flower and flower bud as dietary supplement ingredients found that no serious adverse events or toxicity were reported in the clinical or experimental animal studies reviewed.
9.2 Known Adverse Effects
Some possible side effects of Sophora japonica flower extract may include gastrointestinal discomfort such as nausea, vomiting, or diarrhea in some individuals; in rare cases, it may also cause allergic reactions, especially in those with pre-existing allergies.
Allergic reactions can range from mild symptoms such as skin rashes, itching, and redness to more severe symptoms; people with known allergies to plants in the Fabaceae family (to which Sophora japonica belongs) should be especially cautious when using products containing this extract.
9.3 Drug Interactions
Although some studies indicated that rutin or quercetin may have potential for drug interactions, none were identified specifically for S. japonicum flower or flower bud in the USP safety review. However, constituent-level interaction data are pharmacologically relevant:
Warfarin interaction: In a controlled human study, rutin reduced warfarin's anticoagulant effect by about 31% and shortened S-warfarin half-life, consistent with a clinically meaningful interaction risk. Experimental data suggest rutin can reduce warfarin's anticoagulant effect, so warfarin users should treat this as a high-priority interaction risk.
Anticoagulant/antiplatelet agents: There is a possibility of drug interactions with Sophora japonica flower extract; if taken with medications that also affect blood pressure or blood clotting, it could potentially lead to adverse effects.
9.4 Special Populations
Pregnant or breastfeeding women should avoid the extract as its safety during pregnancy and lactation has not been fully established. People with liver or kidney diseases should also use it with caution.
9.5 Post-Thrombotic Syndrome
A Cochrane review examining rutosides for the prevention of post-thrombotic syndrome (PTS) following deep vein thrombosis (DVT) found: no trials of rutosides versus an alternative therapy for the prevention of PTS that were suitable for inclusion; there is therefore no evidence to support the use of rutosides in the prevention of PTS, and high-quality randomised controlled trials are required.
9.6 Product Standardization Concerns
A "rutin 95%" grade of Sophora japonica extract powder is only as credible as its method transparency and identity confirmation; a single potency number is not an authenticity strategy, especially in a market where spiking and substitution are known risks.
10. Pharmacopeial and Regulatory Status
The use of this plant has been recorded in classical medicinal treatises of ancient China, and it is currently recorded in both the Chinese Pharmacopoeia and the European Pharmacopoeia.
Sophora japonica L. (Fabaceae) is a well-known herbal medicine which has been used in traditional Chinese medicine for a long time; three entries are listed in the Chinese Pharmacopoeia: Huaimi, Flos Sophora immaturus, is the dry flower buds of S. japonica collected in summer.
In the United States, S. japonicum flower and flower bud preparations are marketed as dietary supplements for their anti-oxidative properties and as a source of flavonoids including rutin and quercetin. The United States Pharmacopeia has published monograph standards for Japanese Sophora flower dry extract.
A monograph for Styphnolobium japonicum fruits (Sophora japonica fruits) has also been developed in Russia: based on data obtained, a pharmacopoeial monograph "Styphnolobium japonicum fruits" FS.2.5.0130 was developed and approved, which is included in the State Pharmacopoeia of the Russian Federation, XV edition.
11. Summary of Evidence Gaps and Research Directions
S. japonica has long been used in traditional Chinese medicine due to its wide range of biological activities and is administered orally; phytochemical and pharmacological studies of S. japonica have increased in the past few years, and the extract and active components of this plant can be used to develop new drugs based on their traditional application as well as their biological activities.
Key evidence gaps remain: while historical use and early scientific data support its inclusion in nutritional products, further rigorous research is needed to fully substantiate its health claims and establish standardized dosages. Most mechanistic data concern isolated constituents or semi-synthetic derivatives (e.g., hydroxyethylrutosides) rather than the whole-plant extract. Human clinical trials directly testing standardized S. japonica whole-flower or whole-bud extracts for specific clinical endpoints are lacking for most indications outside venous insufficiency and hemorrhoids.
References
Go back